[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Luz MA, Kotb AF, Aldousari S, Brimo F, Tanguay S, Kassouf W, Aprikian AG: Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol; 2010;8:97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.
  • BACKGROUND: Retroperitoneal lymph node dissection has been advocated for the management of post-chemotherapy (PC-RPLND) residual masses of non-seminomatous germ cell tumors of the testis (NSGCT).
  • Between 1994 and 2008, three surgeons operated 73 patients with residual masses after cisplatin-based chemotherapy for a metastatic testicular cancer.
  • Patients needed to have normal postchemotherapy serum tumor markers, no prior surgical attempts to resect retroperitoneal masses and resectable retroperitoneal tumor mass at surgery to be included in this analysis RESULTS: Mean age was 30.4 years old.
  • The mean size of retroperitoneal metastasis was 6.3 and 4.0 cm, before and post-chemotherapy, respectively.
  • In 56% of patients, the surgeon was able to perform a nerve sparing procedure.
  • CONCLUSION: PC-RPLND is a relatively safe procedure.
  • The presence of fibrosis and large residual masses are associated with surgical complications and non-nerve-sparing procedure.
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / surgery. Retroperitoneal Space. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1998 Aug;25(3):479-84 [9728217.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2):203-9 [9562453.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1235-40 [17665498.001]
  • [Cites] J Urol. 2009 May;181(5):2097-101; discussion 2101-2 [19286227.001]
  • [Cites] Health Rep. 2009 Mar;20(1):7-19 [19388364.001]
  • [Cites] Urol Oncol. 2009 Jul-Aug;27(4):417-21 [19573772.001]
  • [Cites] BJU Int. 2009 Nov;104(9 Pt B):1404-12 [19840021.001]
  • [Cites] Urol Oncol. 2010 Sep-Oct;28(5):504-9 [19097812.001]
  • [Cites] J Urol. 2001 May;165(5):1517-20 [11342909.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1668-76 [11920527.001]
  • [Cites] BJU Int. 2002 Apr;89(6):549-56 [11942962.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):843-7 [12644820.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1329-34 [8055456.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):976-80 [7853586.001]
  • [Cites] J Urol. 1995 Oct;154(4):1373-5 [7544838.001]
  • [Cites] J Urol. 1996 Nov;156(5):1656-8 [8863564.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):843-7 [9291803.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1409-19 [9762943.001]
  • (PMID = 21062470.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Nonseminomatous germ cell tumor
  • [Other-IDs] NLM/ PMC2991320
  •  go-up   go-down


2. Willis SF, Winkler M, Savage P, Seckl MJ, Christmas TJ: Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour. BJU Int; 2007 Oct;100(4):809-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
  • OBJECTIVES: To examine the operative findings, histopathology and clinical outcome of patients undergoing repeat retroperitoneal lymph node dissection (RPLND) after initial chemotherapy and RPLND (PC-RPLND) for metastatic testicular germ cell tumour (GCT), as a small proportion relapse or have residual disease after incomplete resection in the lung, retrocrural or pelvic nodes, and retroperitoneum.
  • RESULTS: The median (range) time from original to repeat surgery was 2.4 (0.25-26.5) years, and the median follow-up after the repeat procedure was 5.8 (0.08-12.9) years.
  • There was no difference in survival between patients requiring only one PC-RPLND and those having a repeat procedure (P = 0.592).
  • The most common pathological findings in the repeat PC-RPLNDs were differentiated teratoma (19, 35%), malignant teratoma undifferentiated (nine, 17%), adenocarcinoma (eight, 15%) and necrotic tissue (five, 9.2%).
  • CONCLUSION: Although a small proportion of patients with metastatic GCT might require repeat PC-RPLND, there is no difference in survival between this group and those having one PC-RPLND.
  • However, to avoid cancer recurrence and reoperation, it is crucial that the first PC-RPLND is careful and complete, preferably done in a centre with expertise in this procedure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymph Node Excision. Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm, Residual. Prognosis. Reoperation. Retroperitoneal Space. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711512.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Nanpo Y, Yamauchi T: [Testicular tumor following orchiopexy: a case report]. Hinyokika Kiyo; 2006 Aug;52(8):655-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 36-year-old male with history of left orchiopexy at age 11 received medical examination at the emergency department of our hospital with a left painful inguinal tumor as the chief complaint.
  • On histopathological examination, the tumor was a seminoma and the left inguinal tumor was a lymph node metastasis (3 x 4 x 5 cm).
  • After operation, the tumor markers became normal and radiographic examination showed no evidence of metastasis to the retroperitoneal lymph nodes and to other organs.
  • Subsequently, the patient was given 2 courses of systemic chemotherapy (bleomycin, etoposide, cisplatin) as an adjuvant therapy.
  • [MeSH-minor] Adult. Humans. Lymphatic Metastasis. Male. Postoperative Complications. Scrotum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972632.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


Advertisement
4. Debnath J, Chawla N, Talwar R, Vohra LS, George RA, Singh HP, Vaidya A, Satija L: Pleural and transdiaphragmatic retroperitoneal metastasis developing two and half years after resection of invasive thymoma. Singapore Med J; 2008 Mar;49(3):e64-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural and transdiaphragmatic retroperitoneal metastasis developing two and half years after resection of invasive thymoma.
  • We report transdiaphragmatic pleural and retroperitoneal metastasis developing two and half years after resection of invasive thymoma (Masaoka stage III; WHO type B1, lymphocyte-rich) in a 34-year-old man.
  • Post-surgery, he received radiotherapy and chemotherapy.
  • Follow-up computed tomography (CT) one year post-surgery did not reveal any local recurrence or metastasis.
  • A follow-up CT done two and half years later revealed an enhancing retrocrural-retroperitoneal (posterior pararenal space) soft tissue mass measuring 12 cm x 10 cm x 6 cm.
  • Histopathology confirmed these lesions to be metastases from the lymphocyte-rich thymoma.
  • [MeSH-major] Diaphragm / pathology. Pleural Neoplasms / secondary. Retroperitoneal Neoplasms / secondary. Thymoma / pathology
  • [MeSH-minor] Adult. Humans. Male. Military Personnel. Singapore. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362988.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


5. Stephenson AJ, Klein EA: Surgical management of low-stage nonseminomatous germ cell testicular cancer. BJU Int; 2009 Nov;104(9 Pt B):1362-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The optimal treatment of low-stage nonseminomatous germ cell testicular cancer (NSGCT) is controversial.
  • For clinical stage (CS) I NSGCT, retroperitoneal lymph node dissection (RPLND), two cycles of chemotherapy and surveillance are all accepted treatment options.
  • For CS IIA-B, standard treatments include RPLND (+/- adjuvant chemotherapy) and induction chemotherapy (+/- RPLND).
  • The long-term survival rate is >97% for CS I and 95% for CS IIA-B NSGCT, regardless of the treatment received.
  • The risk of retroperitoneal metastasis varies by clinical stage (25-35% for CS I, 65-85% for CS IIA-B), and the presence of lymphovascular invasion and percentage of embryonal carcinoma in the primary tumour.
  • Compared with chemotherapy, RPLND is associated with a considerably more favourable long-term morbidity profile and is the most effective method for controlling the retroperitoneum.
  • As such, we favour surveillance for low-risk CS I, induction chemotherapy for those at high risk of systemic disease (elevated STM, adenopathy >3 cm), and RPLND for all others.
  • The therapeutic efficacy of laparoscopic RPLND is not proven and currently should be considered a staging procedure only.
  • Adjuvant chemotherapy after RPLND is typically restricted to patients with pathological stage N2-3 disease.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Laparoscopy / methods. Lymph Node Excision / methods. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / prevention & control. Orchiectomy / methods. Retroperitoneal Neoplasms / surgery. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840014.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


6. Boghossian V, Owen ID, Nuli B, Xiao PQ: Neuroendocrine (Merkel cell) carcinoma of the retroperitoneum with no identifiable primary site. World J Surg Oncol; 2007;5:117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine (Merkel cell) carcinoma of the retroperitoneum with no identifiable primary site.
  • BACKGROUND: Neuroendocrine carcinoma is an aggressive neoplasm that mainly affects elderly Caucasians and typically arises in sun-exposed areas of the skin.
  • CASE PRESENTATION: We report a case of an 81-year-old Caucasian male with neuroendocrine carcinoma, which initially presented as a large retroperitoneal mass.
  • Pathological and immunohistochemical analysis of the transabdominal CT-guided biopsy specimen revealed tissue consistent with neuroendocrine carcinoma.
  • First, the retroperitoneal mass could be a massively enlarged lymph node where precursor cells became neoplastic.
  • This would be consistent with a presumptive diagnosis of primary nodal disease.
  • Alternatively, an initial skin lesion could have spontaneously regressed and the retroperitoneal mass represents a single site of metastasis.
  • Moreover, metastasis to the retroperitoneal lymph nodes has been reported as relatively common when compared to other sites such as liver, bone, brain and skin.
  • CONCLUSION: Wide local excision of the primary tumor is the surgical treatment of choice for localized disease.
  • We propose that further studies are needed to elucidate the true efficacy of chemotherapy in conventional as well as unconventional patients with neuroendocrine carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Carcinoma, Neuroendocrine / secondary. Lymph Nodes / pathology. Neoplasms, Unknown Primary / pathology. Retroperitoneal Neoplasms / secondary
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy / methods. Male. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2000 Jan-Feb;7(1):72-83 [10740663.001]
  • [Cites] Australas J Dermatol. 2006 Aug;47(3):160-5 [16866994.001]
  • [Cites] Am Surg. 2001 Oct;67(10):943-7 [11603550.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115 Suppl:S68-78 [11993692.001]
  • [Cites] Plast Reconstr Surg. 2002 Oct;110(5):1259-65 [12360064.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):515-7 [12789943.001]
  • [Cites] Isr Med Assoc J. 2003 Jun;5(6):450-1 [12841023.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(5):609-26 [3092460.001]
  • [Cites] Ann Surg. 1988 Feb;207(2):201-7 [3277546.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6 [2170468.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):658-66 [1530107.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):143-56 [8335732.001]
  • [Cites] Am J Otolaryngol. 1997 Jan-Feb;18(1):55-65 [9006679.001]
  • [Cites] Semin Cutan Med Surg. 1998 Jun;17(2):114-32 [9669605.001]
  • [Cites] J Am Acad Dermatol. 1998 Nov;39(5 Pt 2):882-7 [9810922.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):856-8 [15557979.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] ANZ J Surg. 2005 May;75(5):275-81 [15932436.001]
  • [Cites] J Cutan Med Surg. 2000 Oct;4(4):186-95 [11231196.001]
  • (PMID = 17949500.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2117014
  •  go-up   go-down


7. Zuo CJ, Wang PJ, Shao CW, Wang MJ, Tian JM, Xiao Y, Ren FY, Hao XY, Yuan M: CT-guided percutaneous ethanol injection with disposable curved needle for treatment of malignant liver neoplasms and their metastases in retroperitoneal lymph nodes. World J Gastroenterol; 2004 Jan;10(1):58-61
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT-guided percutaneous ethanol injection with disposable curved needle for treatment of malignant liver neoplasms and their metastases in retroperitoneal lymph nodes.
  • AIM: To explore the feasibility of computed tomography (CT)-guided percutaneous ethanol injection (PEI) using a disposable curved needle for treatment of malignant liver neoplasms and their metastases in retroperitoneal lymph nodes.
  • METHODS: CT-guided PEI was conducted using a disposable curved needle in 26 malignant liver tumors smaller than 5 cm in diameter and 5 lymph node metastases of liver cancer in the retroperitoneal space.
  • The disposable curved needle was composed of a straight trocar (21G) and stylet, a disposable curved tip (25 G) and a fine stylet.
  • For relatively large malignant liver tumors, multi-point injection was carried out for a better distribution of the ethanol injected throughout the masses.
  • The curved needle was also used for treatment of the metastasis in retroperitoneal lymph nodes blocked by blood vessels and inaccessible by the straight needle.
  • RESULTS: All of the 26 liver tumors received 2 or more times of successful PEI, through which ethanol was distributed throughout the whole tumor mass.
  • Effect of the treatment was monitored by contrast-enhanced multi-phase CT and magnetic resonance imaging (MRI) examinations three months later.
  • In 5 patients with metastases of liver cancer in retroperitoneal lymph nodes who received 1 to 3 times of PEI, all the foci treated were completely necrotic and smaller demonstrated by dynamic contrast-enhanced CT or MRI 3 months later.
  • CONCLUSION: CT-guided PEI using a disposable curved needle is effective, time-saving and convenient, providing an alternative therapy for the treatment of malignant liver tumors and their retroperitoneal lymph node metastases.
  • [MeSH-major] Ethanol / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Solvents / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Nodes. Lymphatic Metastasis. Male. Middle Aged. Needles. Retroperitoneal Space. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14695769.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Solvents; 3K9958V90M / Ethanol
  • [Other-IDs] NLM/ PMC4717079
  •  go-up   go-down


8. Lev-Chelouche D, Nakache R, Soffer D, Merimsky O, Klausner MJ, Gutman M: Metastases to the retroperitoneum in patients with extremity soft tissue sarcoma: an unusual metastatic pattern. Cancer; 2000 Jan 15;88(2):364-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases to the retroperitoneum in patients with extremity soft tissue sarcoma: an unusual metastatic pattern.
  • BACKGROUND: Extremity soft tissue sarcoma (STS) metastasizes preferentially to the lungs via the hematogenous route.
  • Metastases in extrapulmonary sites such as bone, brain, and subcutaneous tissues are observed less frequently.
  • To the authors' knowledge, limb STS primarily metastasizing to the retroperitoneum has not been described to date.
  • The current study reviews the clinical course, management, and patient prognosis in such a pattern of metastasis.
  • METHODS: Records of patients with retroperitoneal metastases originating from an extremity STS between 1994-1998 were reviewed.
  • Patient demographics, primary tumor site, other tumor sites, local recurrence, distant metastasis, treatment, and survival were analyzed.
  • All had primary STS of different histologic types and high histologic grade confined to a lower limb.
  • The retroperitoneal metastases were diagnosed between 6-120 months (mean, 45 months) after diagnosis of the primary sarcoma.
  • At that time, one patient had evidence of local recurrence of the primary tumor site, two patients had lung metastases, and one patient had diffuse bone metastases.
  • In six of these patients the metastases were excised completely.
  • Two patients with recurrent retroperitoneal disease and one patient with retroperitoneal and lung metastases died despite systemic chemotherapy.
  • CONCLUSIONS: Extremity STS can metastasize hematogenously to the retroperitoneum, a fact that mandates a high index of suspicion and abdominal imaging studies during the follow-up of such patients.
  • Retroperitoneal metastases necessitate aggressive surgical resection to enable prolongation of survival.
  • [MeSH-major] Retroperitoneal Neoplasms / secondary. Sarcoma / secondary. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10640969.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


9. Janetschek G: Laposcopic retroperitoneal lymph node dissection: evolution of a new technique. World J Urol; 2000 Sep;18(4):267-71
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laposcopic retroperitoneal lymph node dissection: evolution of a new technique.
  • Retroperitoneal lymph node dissection is the most accurate method of detecting occult lymph node metastases in the retroperitoneum.
  • In clinical stage II disease, a residual tumor after primary chemotherapy has to be removed surgically.
  • Once the learning curve had been overcome, the operative time was in the range of that of open surgery, and from the very beginning morbidity and complication rates were lower.
  • [MeSH-major] Laparoscopy. Lymph Node Excision / methods. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Quality of Life. Retroperitoneal Space. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11000309.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 30
  •  go-up   go-down


10. Beck SD, Cheng L, Bihrle R, Donohue JP, Foster RS: Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy? J Urol; 2007 Mar;177(3):944-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy?
  • PURPOSE: The presence of extranodal extension identified at primary retroperitoneal lymph node dissection has been associated with an increased risk of disease recurrence, and as such these patients are sometimes treated with adjuvant chemotherapy.
  • We decided to evaluate the significance of extranodal extension on disease-free survival in patients with pathological stage B nonseminomatous germ cell tumor who did not receive adjuvant chemotherapy.
  • MATERIALS AND METHODS: A retrospective review of our testicular cancer database was performed to identify all patients with clinical stage A nonseminomatous germ cell tumor who underwent primary retroperitoneal lymph node dissection and were found to have retroperitoneal metastasis with 5 or fewer involved nodes and no metastatic node larger than 2 cm.
  • No patient received adjuvant chemotherapy, and all had a minimum followup of 24 months.
  • A single pathologist (LC), who was blinded to clinical outcome, reviewed the retroperitoneal nodal package to identify the presence or absence of extranodal extension, defined as cancer perforating through the lymph node capsule into perinodal tissue.
  • RESULTS: A total of 80 patients were identified with a median followup 48 months, and a 2 and 5-year disease-free survival of 75%.
  • Extranodal extension was present in 23 patients and absent in 57 patients with a median followup of 54 and 44 months, respectively.
  • CONCLUSIONS: We were unable to detect any prognostic significance of extranodal extension in patients found to have retroperitoneal metastasis at primary retroperitoneal lymph node dissection.
  • [MeSH-major] Lymph Node Excision. Lymph Nodes / pathology. Neoplasms, Germ Cell and Embryonal / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Cohort Studies. Disease-Free Survival. Humans. Male. Orchiectomy. Predictive Value of Tests. Retroperitoneal Space. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296383.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Sendler A, Strumberg D, Tannapfel A: [Carcinoma of unknown primary site (CUP syndrome)]. Chirurg; 2008 Jul;79(7):689-95; quiz 696
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the growing array of sophisticated diagnostic tools for establishing a diagnosis of human neoplasia, 2-6% of all cancer patients still present metastatic cancer of which detailed investigations fail to identify the primary anatomic site.
  • At the time of first diagnosis with carcinoma of unknown primary site, usually more than 80% of patients present with dissemination.
  • Node dissection may be curative for patients with metastases to peripheral lymph nodes.
  • Objective long-term response is possible in combination with chemotherapy in patients with small-cell malignancies, peritoneal carcinomatosis (in women), or poorly differentiated carcinomas involving external lymph nodes, mediastinum, or retroperitoneum but without metastases to viscera or bone.
  • Toxic therapies are recommended only for palliation of symptoms and maintaining quality of life support in patients with good functional status.
  • Patients should be encouraged to participate in clinical trials for novel therapies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):47-58 [12667308.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):205-11 [11856596.001]
  • [Cites] Pathologe. 2002 May;23(3):183-97 [12089786.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):425-31 [11407517.001]
  • [Cites] Onkologie. 2001 Feb;24(1):38-43 [11441279.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Ann Oncol. 2001 Nov;12 (11):1605-9 [11822762.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):147-52 [11884050.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3611-3 [12552964.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1073-7 [12475531.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • [Cites] Urologe A. 2006 May;45(5):614-9 [16710679.001]
  • (PMID = 18584137.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Seeber S, Strumberg D: [Metastases with CUP syndrome]. Urologe A; 2006 May;45(5):614-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastases with CUP syndrome].
  • [Transliterated title] Metastasen mit unbekanntem Primärtumor (CUP).
  • At the time point of first diagnosis of CUP syndrome, usually more than 80% of the patients present a disseminated situation.
  • For patients presenting with metastasis to peripheral lymph nodes, node dissection may be curative.
  • In patients with small cell malignancies, peritoneal carcinomatosis (in women), poorly differentiated carcinomas involving external lymph nodes, mediastinum, or retroperitoneum, but without metastases to viscera or bone, objective long-term responses are possible with combination chemotherapy.
  • For all other patients, toxic therapies are recommended only for patients with good functional status, for palliation of symptoms when they develop, and for continuous support of the quality of life.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / drug therapy. Palliative Care / methods. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / secondary
  • [MeSH-minor] Clinical Trials as Topic. Humans. Neoplasm Recurrence, Local / prevention & control. Practice Guidelines as Topic. Practice Patterns, Physicians'. Quality of Life. Syndrome. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Jan 1;57(1):120-4 [3940611.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):47-58 [12667308.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):210-4 [2302061.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):205-11 [11856596.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1720-5 [7541451.001]
  • [Cites] Pathologe. 2002 May;23(3):183-97 [12089786.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):425-31 [11407517.001]
  • [Cites] Arch Intern Med. 1988 Sep;148(9):2035-9 [3046543.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Anticancer Res. 1993 Sep-Oct;13(5A):1619-23 [8239543.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):206-28 [8503017.001]
  • [Cites] Cancer Res. 1989 Aug 1;49(15):4311-5 [2743318.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5092-4 [15107816.001]
  • [Cites] Onkologie. 2001 Feb;24(1):38-43 [11441279.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Bull Cancer. 2001 Jun;88(6):619-27 [11459709.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1160-6 [9506364.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] J Pathol. 2001 Sep;195(1):41-52 [11568890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):143-7 [10758316.001]
  • [Cites] Ann Oncol. 2001 Nov;12 (11):1605-9 [11822762.001]
  • [Cites] Ugeskr Laeger. 2001 Mar 5;163(10):1432-6 [11257752.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):273-8 [8503023.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2056-66 [9164218.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):147-52 [11884050.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):43-8 [12542974.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3611-3 [12552964.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Wien Klin Wochenschr. 1989 Jul 14;101(14):464-72 [2672606.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1073-7 [12475531.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • (PMID = 16710679.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 40
  •  go-up   go-down


13. Mohanty SK, Balani JP, Parwani AV: Primitive neuroectodermal tumor arising in a testicular teratoma with retroperitoneal metastasis: report of an interesting case with review of literature. Urology; 2007 Oct;70(4):812.e7-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor arising in a testicular teratoma with retroperitoneal metastasis: report of an interesting case with review of literature.
  • Teratomas with malignant transformation occur in approximately 3 to 6% of patients with metastatic germ cell tumors treated with platinum-based chemotherapy.
  • The histology of the nongerm cell (somatic) malignant elements most commonly includes carcinoma and various types of sarcomas; however, so far as the primitive neuroectodermal tumors (PNETs) are concerned the experience is quite limited.
  • There are only seven documented case reports and occasional series of PNET in association with testicular teratoma either in the primary site or in the metastatic location.
  • We report a relatively unusual case of PNET arising in a malignant mixed germ cell tumor in a 35-year-old man.
  • [MeSH-major] Neoplasms, Second Primary. Neuroectodermal Tumors, Primitive / pathology. Retroperitoneal Neoplasms / secondary. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991577.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


14. Uría González-Tova J, Escalera Almendros C, Sánchez Macias J, Areal Calama J, Sanfeliú Cortes F, Ibarz Servio L, Saladie Roig JM: [Malignant mesothelioma of the tunica vaginalis]. Actas Urol Esp; 2000 Oct;24(9):757-60
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mesothelioma of the tunica vaginalis].
  • Case report of a new case of malignant mesothelioma of the tunica vaginalis testis.
  • After surgery (orchiectomy and partial hemiscrotectomy) and histopathology diagnosis of locally advanced malignant mesothelioma, CT showed metastasis in retroperitoneum, Lung and Liver.
  • The patient undergoes chemotherapy and radiotheraphy with a poor prognose.
  • We review the diagnosis, histopathology and therapeutical approach for this uncommon kind of paratesticular tumor (less than 80 cases reported in the last 30 years).

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132449.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


15. Dinis da Gama A, Vilhena-Ayres J, Silva E, Passos Coelho P, Oliveira PS: [Germ cell tumor of the testis with invasion of inferior vena cava. Multidisciplinary surgical management]. Rev Port Cir Cardiotorac Vasc; 2008 Jul-Sep;15(3):163-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumor germinativo testicular com invasão da veia cava inferior. Tratamento cirúrgico multidisciplinar.
  • The authors report the clinical case of a 34 years old male, with a germ cell tumor of the testis, who developed large retroperitoneal metastasis, with compression and later on invasion of the inferior vena cava.
  • The patient underwent chemotherapy followed by resection of the original tumor and of the retroperitoneal metastasis and the vena cava was replaced by a vascular prosthesis.
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19116682.001).
  • [ISSN] 0873-7215
  • [Journal-full-title] Revista portuguesa de cirurgia cardio-torácica e vascular : órgão oficial da Sociedade Portuguesa de Cirurgia Cardio-Torácica e Vascular
  • [ISO-abbreviation] Rev Port Cir Cardiotorac Vasc
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 8
  •  go-up   go-down


16. Amin MU, Shafique M: Isolated malignant peripheral nerve sheath tumor of retroperitoneum. J Coll Physicians Surg Pak; 2007 Apr;17(4):226-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated malignant peripheral nerve sheath tumor of retroperitoneum.
  • A case of an isolated Malignant Peripheral Nerve Sheath Tumor (MPNST) of the retroperitoneum without neurofibromatosis is presented.
  • The tumor was located deep in the retroperitoneum with metastasis to the ribs.
  • Patient was further managed with radiotherapy and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462183.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


17. Chiewvit P, Danchaivijitr N, Sirivitmaitrie K, Chiewvit S, Thephamongkhol K: Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis? J Med Assoc Thai; 2009 Jun;92(6):818-29
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis?
  • OBJECTIVE: To determine the role of Magnetic Resonance (MR) imaging for the investigation ofpatients with suspected metastasis to the spine by bone scintigraphy.
  • MATERIAL AND METHOD: Retrospectively reviewed with comparison was made between Technetium-99m Methylene Diphosphonate (99(m)Tc-MDP) bone scintigraphy and corresponding spine MR images in 48 cases of vertebral metastasis at Siriraj Hospital.
  • The MR imaging findings were studied: location (cervical or thoracic or lumbar or sacrum spine), number of lesions (solitary or multiple lesions), pattern of enhancement (homogeneous or inhomogeneous), involvement of spinal canal, compression of spinal cord, extradural extension, other incidental findings such as pulmonary metastasis, pleural effusion, lymphadenopathy The final diagnosis was confirmed clinically and followed-up for further management (radiation or surgery) or followed-up by MR imaging (1 month-16 months) and bone scintigraphy (5 months-12 months).
  • RESULTS: Forty-eight cases (80 lesions) of vertebral metastasis were identified (25 men and 23 women; mean age 61 years and range 8-84 years).
  • Primary neoplasms include breast cancer (n=11), colorectal cancer (n=7), lung cancer (n=6), prostate cancer (n=5), nasopharyngeal cancer (n=5), head and neck cancer (n=3), thyroid cancer (n=2), liver cancer (n=2), esophagus cancer (n=1), bladder cancer (n=1), retroperitoneum cancer (n=1), medulloblastoma (n=1), cervical cancer (n=1), ovarian cancer (n=1), malignant melanoma (n=1).
  • The result of bone scintigraphy and MR imaging is used to evaluate vertebral metastasis: in 44 lesions of bone scintigraphy positive for vertebral metastasis, 40/44 lesions (91%) which MR imaging reveal vertebral metastasis.
  • In 24 lesions of negative of bone scintigraphy for vertebral metastasis, the authors found that 14/24 lesions (58%) showed positive of vertebral metastasis from MR imaging.
  • MR imaging demonstrated metastatic cord compression in 16 cases.
  • CONCLUSION: The authors conclude that the MR imaging is more efficient than the bone scintigraphy in detecting vertebral metastasis, especially in the cases that bone scintigraphy are equivocal or negative for vertebral metastasis in high clinical suspicion.
  • Furthermore, MR imaging is important for the further treatment planning such as radiation therapy or systemic chemotherapy.
  • Although MR imaging is useful in the detection of early metastasis that are localized completely in the bone marrow cavity routinely bone scintigraphy remains that most cost-effective method for examination of the entire skeleton.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diphosphonates. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / radionuclide imaging. Organotechnetium Compounds. Radionuclide Imaging. Retrospective Studies. Spinal Cord Compression. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530588.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
  •  go-up   go-down


18. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL: Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics; 2002 Jul-Aug;22(4):911-34
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They arise wherever sympathetic tissue exists and may be seen in the neck, posterior mediastinum, adrenal gland, retroperitoneum, and pelvis.
  • Ganglioneuroblastoma is composed of both mature gangliocytes and immature neuroblasts and has intermediate malignant potential.
  • Neuroblastoma is the most immature, undifferentiated, and malignant tumor of the three.
  • Neuroblastoma, however, may have a relatively benign course, even when metastatic.
  • Treatment consists of surgery and, usually, chemotherapy.
  • Despite recent advances in treatment, including bone marrow transplantation, neuroblastoma remains a relatively lethal tumor, accounting for 10% of pediatric cancers but 15% of cancer deaths in children.
  • [MeSH-minor] Ganglioneuroblastoma / pathology. Ganglioneuroblastoma / radiography. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Prognosis. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2002
  • (PMID = 12110723.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


19. Benedetti G, Rastelli F, Fedele M, Castellucci P, Damiani S, Crinò L: Presentation of nonseminomatous germ cell tumor of the testis with symptomatic solitary bone metastasis. A case report with review of the literature. Tumori; 2006 Sep-Oct;92(5):433-6
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for nonseminomatous germ cell tumor .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation of nonseminomatous germ cell tumor of the testis with symptomatic solitary bone metastasis. A case report with review of the literature.
  • Metastatic bone lesions are exceptional at diagnosis in germ cell tumors (GCTs).
  • Bone involvement is usually a late event combined with synchronous metastasis in the retroperitoneal lymph nodes, lung and liver.
  • Bone examination is not considered a standard procedure in the staging of GCTs, and this may contribute to underestimation of the real proportion of bone metastases.
  • Here we report a case of nonseminomatous GCT of the testis with a synchronous, symptomatic, solitary pubic bone metastasis that was completely controlled by systemic chemotherapy and locoregional radiation therapy.
  • Solitary bone metastases from GCTs seem to be chemosensitive and radiosensitive, but we do not know their prognostic value.
  • We propose individualized management for symptomatic GCT patients including bone scintigraphy and/or PET examination at diagnosis and a combined cytotoxic approach with chemotherapy and radiation therapy.
  • [MeSH-major] Bone Neoplasms / secondary. Neoplasms, Germ Cell and Embryonal / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Positron-Emission Tomography. Radiotherapy, Adjuvant. Tomography, X-Ray Computed


20. Lee SH, Lee KB, Shin JW, Chung DH, Park CY: Ovarian malignant melanoma without evidence of teratoma. J Obstet Gynaecol Res; 2010 Aug;36(4):898-901
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian malignant melanoma without evidence of teratoma.
  • A 46-year-old woman with ovarian malignant melanoma had advanced intraperitoneal metastasis, retroperitoneal and inguinal lymph node metastases.
  • Extensive debulking surgery was performed and chemotherapy was given.
  • Despite the surgery and chemotherapy, the patient died within 2 months of diagnosis.
  • Considering this case, it is assumed that the combination of surgical debulking and chemotherapy are not always beneficial in ovarian malignant melanoma and the prognosis of ovarian malignant melanoma is very poor.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666966.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


21. Hofmann U, O'Connor JP, Biyani CS, Harnden P, Selby P, Weston PM: Retroperitoneal metastatic squamous cell carcinoma of the tonsil (with elevated beta human chorionic gonadotrophin): a misdiagnosis as extra-gonadal germ cell tumour. J Laryngol Otol; 2006 Oct;120(10):885-7
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal metastatic squamous cell carcinoma of the tonsil (with elevated beta human chorionic gonadotrophin): a misdiagnosis as extra-gonadal germ cell tumour.
  • Metastasis to distant lymph node groups is a rare event.
  • Furthermore, delayed multiple metastases without local recurrence is relatively uncommon.
  • A case of retroperitoneal metastasis from a squamous cell carcinoma of the tonsil, secreting beta human chorionic gonadotrophin (beta-hCG), is reported.
  • A computed tomography scan demonstrated para-aortic retroperitoneal lymphadenopathy.
  • The initial pathological analysis was interpreted as extra-gonadal germ cell tumour and the patient received chemotherapy.
  • A subsequent review was consistent with a metastatic squamous cell carcinoma of the tonsil, as immunohistochemical studies showed positive staining for epithelial membrane antigen and cytokeratins 5/6 but a negative reaction to placental alkaline phosphatase.
  • Following this, the chemotherapy regimen was changed; however, a restaging scan demonstrated progression, and the patient died from aspiration pneumonia secondary to alcohol intoxication.
  • To our knowledge, this is the first reported case of retroperitoneal metastasis from a squamous cell carcinoma of the tonsil, secreting beta-hCG and causing hydronephrosis.
  • This case highlights the necessity of using clinical, histological, immunohistological and ultrastructural examination to establish precise diagnosis and to avoid inappropriate treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Diagnostic Errors. Neoplasms, Germ Cell and Embryonal / diagnosis. Retroperitoneal Neoplasms / diagnosis. Tonsillar Neoplasms
  • [MeSH-minor] Chorionic Gonadotropin, beta Subunit, Human / blood. Fatal Outcome. Humans. Hydronephrosis / complications. Male. Middle Aged. Neoplasm Proteins / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716237.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
  •  go-up   go-down


22. Houlgatte A: [Surgical management of retroperitoneal metastases from germ cell cancers]. Prog Urol; 2008 Nov;18 Suppl 7:S382-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management of retroperitoneal metastases from germ cell cancers].
  • [Transliterated title] Prise en charge chirurgicale des métastases rétropéritonéales des tumeurs germinales du testicule.
  • The surgery of residual retroperitoneal tumors is a compulsory prolongation of chemotherapy in non seminomatous germ cell tumors.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / surgery. Retroperitoneal Neoplasms / secondary. Retroperitoneal Neoplasms / surgery. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070819.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Hara H, Igarashi A, Yano Y, Yashiro T, Ueno E, Aiyoshi Y: Interventricular methotrexate therapy for carcinomatous meningitis due to breast cancer: a case with leukoencephalopathy. Breast Cancer; 2000;7(3):247-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventricular methotrexate therapy for carcinomatous meningitis due to breast cancer: a case with leukoencephalopathy.
  • She had had a radical mastectomy for left breast cancer 10 years earlier, and 6 months prior to presentation she completed CMF chemotherapy for treatment of retroperitoneal metastasis.
  • CT and MRI to identify potential causes of the paraplegia and lumbago showed leptomeningeal carcinomatosis due to dissemination from invasive recurrence of the retroperitoneal tumor.
  • Although administration of prednisolone mostly resolved her symptom, the patient died 9 months after the diagnosis of carcinomatous meningitis.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / secondary. Leukoencephalitis, Acute Hemorrhagic / chemically induced. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Methotrexate / adverse effects. Retroperitoneal Neoplasms / secondary
  • [MeSH-minor] Biopsy. Fatal Outcome. Female. Humans. Injections, Intraventricular. Low Back Pain / etiology. Magnetic Resonance Imaging. Mastectomy, Radical. Middle Aged. Paraplegia / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11029806.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Zhang XQ, Liu ZW, Zhou FJ, Han H, Qin ZK, Ye YL, Li YH, Hou GL, Zhang ZL: [Experience of the treatment for clinical Stage-1 seminoma over a period of 10 years]. Chin J Cancer; 2010 Jan;29(1):98-101
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of the treatment for clinical Stage-1 seminoma over a period of 10 years].
  • This study was to analyze the relationship between different therapeutic methods and the prognosis of this disease.
  • The patients were divided into 3 groups based on the treatment they received after orchiectomy: 30 patients treated with chemotherapy, 8 with radiotherapy, and 20 under surveillance.
  • The prognosis of different treatment groups was evaluated.
  • The median follow-up time was 50 months (range, 8-115 months).
  • No relapse or metastasis was seen in the chemotherapy group.
  • Four patients had metastasis of retroperitoneal lymph node in the surveillance group.
  • The disease-free survival was higher in the chemotherapy group than that in the surveillance group (P=0.005).
  • CONCLUSIONS: Chemotherapy is a safe and effective treatment for patients with Stage-1 seminoma after radical orchidectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Orchiectomy. Seminoma. Testicular Neoplasms
  • [MeSH-minor] Adolescent. Adult. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Etoposide / therapeutic use. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038319.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol; VP-P protocol
  •  go-up   go-down


25. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL: Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol; 2003 Jun;169(6):2113-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?
  • PURPOSE: We identified a subset of patients with bladder cancer (transitional cell carcinoma) and regional nodal metastasis to the retroperitoneal lymph nodes without detectable systemic dissemination.
  • While the majority of these patients respond initially to chemotherapy, most have disease relapse at the same site within a year.
  • We report the results of a phase II study exploring the potential benefit of retroperitoneal lymph node dissection in patients with transitional cell carcinoma of the bladder in whom disease has shown a significant response to chemotherapy.
  • MATERIALS AND METHODS: A total of 11 patients with biopsy proven metastatic transitional cell carcinoma in the retroperitoneal lymph nodes and no evidence of visceral metastatic disease in whom disease showed a significant response to chemotherapy underwent complete bilateral retroperitoneal lymph node dissection.
  • The end point of study was disease specific survival, calculated from the time of retroperitoneal lymph node dissection to death from transitional cell carcinoma of the bladder.
  • RESULTS: Four patients underwent delayed retroperitoneal lymph node dissection.
  • Seven patients underwent concurrent cystectomy, and pelvic and retroperitoneal lymph node dissection.
  • Nine patients had evidence of residual disease in the retroperitoneal nodes.
  • Seven patients have recurrence outside of the original surgical field with a median time to recurrence of 7 months and 6 died at a median time to death of 8 months (range 5 to 14).
  • One patient with retrocrural recurrence attained a complete response to salvage chemotherapy and remained disease-free 57 months after retroperitoneal lymph node dissection.
  • We stratified the patients based on the number of involved lymph nodes at retroperitoneal lymph node dissection and noted that viable tumor in no more than 2 lymph nodes correlated with greater disease specific and recurrence-free survival (p = 0.006 and 0.01, respectively).
  • CONCLUSIONS: Retroperitoneal lymph node dissection can be safely performed for metastatic transitional cell carcinoma.
  • Retroperitoneal lymph node dissection has curative potential, particularly in patients with viable tumor in no more than 2 lymph nodes after chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / secondary. Lymph Node Excision. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Humans. Lymphatic Metastasis. Retroperitoneal Space. Survival Rate

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771730.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


26. Li Y, Jiang Y, Song S: [Diagnosis and treatment of primary retroperitoneal teratoma]. Zhonghua Wai Ke Za Zhi; 2000 Dec;38(12):892-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary retroperitoneal teratoma].
  • OBJECTIVE: To study the diagnosis and treatment of primary retroperitoneal teratoma in adults.
  • METHODS: The clinical data of 36 adult patients with primary retroperitoneal teratoma were reviewed.
  • Twenty-four patients (66.7%) aged (30.4 +/- 8.0) years were benign, and 12 patients (36.3%) aged (39.6 +/- 10.5) years were malignant.
  • Four (21.1%) cases of presacral tumors and 8 (47.1%) of 17 cases of epigastric tumors were malignant.
  • All patients, except one with liver metastasis, underwent radical resection.
  • Patients without malignant metastasis survived, but 5 patients with malignant metastasis survived more than 2 years after operation.
  • CONCLUSIONS: Malignant metastasis of retroperitoneal teratoma is closely related to the age of adults.
  • Early radical resection is the optimal treatment.
  • Adjuvant chemotherapy can induce a short-time remission in those with germ cell elements.
  • [MeSH-major] Retroperitoneal Neoplasms. Testicular Neoplasms

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11832188.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement